Dietary phosphate ions (Pi)

Dietary phosphate ions in the gastrointestinal lumen are the primary source of systemic phosphorus, an essential mineral required for skeletal integrity, energy metabolism via ATP, and intracellular signaling (NIH, 2023). In healthy individuals, phosphate homeostasis is maintained through a balance of intestinal absorption and renal excretion; however, in patients with Chronic Kidney Disease (CKD), impaired renal function leads to the accumulation of phosphate in the blood, a condition known as hyperphosphatemia (Kidney International, 2017). This target is unique as it is an inorganic ion rather than a protein, yet it is the direct focus of phosphate binder therapy. These binders are orally administered to sequester luminal phosphate ions, forming insoluble complexes that prevent their absorption into the bloodstream (Journal of Nephrology, 2020). Reducing the systemic absorption of phosphate is critical for preventing secondary hyperparathyroidism, bone disease, and life-threatening vascular calcification in renal patients (Lancet, 2019). Common therapeutic agents include calcium-based salts, sevelamer, and iron-based binders like sucroferric oxyhydroxide.

Other names

Inorganic phosphateOrthophosphateLuminal phosphatePO4Phosphate

Phosphate binders act by physically sequestering or chelating inorganic phosphate ions within the gastrointestinal lumen to form insoluble, non-absorbable complexes that are subsequently excreted in the feces, thereby preventing their entry into the systemic circulation (StatPearls, 2023; Journal of Renal Nutrition, 2021).